The Division of Cancer Sciences encompasses research groups looking at both basic and translational cancer research.
Targeted Cancer Therapy Group
Targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesisand tumour growth, rather than by simply interfering with all rapidly dividing cells as does current therapies such as chemotherapy. The ultimate aim is to kill the tumour with minimal side effects to the patient. The Targeted Cancer Therapy group, based at The University of Surrey and led by Professor Pandha, are working on several projects:
Investigating so-called oncolytic viruses (viruses that solely replicate in cancer cells causing them to die) including herpes simplex virus (HSV) and reovirus in bladder and prostate models.
Using the tumour associated protein EN2 to target tumour cells for both therapy (vaccines and targeted antibodies) and imaging.
Setting up a bio-repository and accompanying ‘database’ of 300 patients with all stages of prostate cancer to allow longitudinal blood sampling whilst on different treatment programs, and enable banking and analysis of serum and DNA at 6 monthly intervals.
Novel Cancer Trials:
A clinical team of 12 staff are developing a large programme of clinical research directed at improved treatment for cancer, understanding the causes of cancer and developing new methods of detection.